| Characteristic | N | Overall, N = 501 | HBV DNA | p-value2 | |
|---|---|---|---|---|---|
| Negative, N = 91 | Positive, N = 411 | ||||
| Age | 50 | 34 (26, 39) | 35 (33, 41) | 32 (24, 39) | 0.3 |
| Age_group | 49 | 0.5 | |||
| < 19 | 3 (6.1%) | 1 (11%) | 2 (5.0%) | ||
| 20-29 | 15 (31%) | 1 (11%) | 14 (35%) | ||
| 30-39 | 19 (39%) | 4 (44%) | 15 (38%) | ||
| 40-49 | 9 (18%) | 2 (22%) | 7 (18%) | ||
| 50-59 | 3 (6.1%) | 1 (11%) | 2 (5.0%) | ||
| HIV-1 | 50 | ||||
| Positive | 50 (100%) | 9 (100%) | 41 (100%) | ||
| HBsAg | 50 | ||||
| Positive | 50 (100%) | 9 (100%) | 41 (100%) | ||
| Genotype | 50 | <0.001 | |||
| A | 43 (86%) | 2 (22%) | 41 (100%) | ||
| None | 7 (14%) | 7 (78%) | 0 (0%) | ||
| Sub Genotypes | 50 | <0.001 | |||
| A1 | 39 (78%) | 2 (22%) | 37 (90%) | ||
| A2 | 4 (8.0%) | 0 (0%) | 4 (9.8%) | ||
| None | 7 (14%) | 7 (78%) | 0 (0%) | ||
| RT mutations | 50 | 9 (6, 12) | 0 (0, 0) | 10 (7, 13) | <0.001 |
| SHB protein | 50 | 6.0 (3.0, 7.0) | 0.0 (0.0, 0.0) | 6.0 (4.0, 8.0) | <0.001 |
| Lamivudine | 50 | <0.001 | |||
| No sequence | 8 (16%) | 7 (78%) | 1 (2.4%) | ||
| Resistant | 6 (12%) | 1 (11%) | 5 (12%) | ||
| Susceptible | 36 (72%) | 1 (11%) | 35 (85%) | ||
| Adefovir | 50 | <0.001 | |||
| No sequence | 8 (16%) | 7 (78%) | 1 (2.4%) | ||
| Resistant | 1 (2.0%) | 0 (0%) | 1 (2.4%) | ||
| Susceptible | 41 (82%) | 2 (22%) | 39 (95%) | ||
| Entecavir | 50 | <0.001 | |||
| No sequence | 8 (16%) | 7 (78%) | 1 (2.4%) | ||
| Resistant | 6 (12%) | 0 (0%) | 6 (15%) | ||
| Susceptible | 36 (72%) | 2 (22%) | 34 (83%) | ||
| Tenofovir | 50 | <0.001 | |||
| No sequence | 8 (16%) | 7 (78%) | 1 (2.4%) | ||
| Susceptible | 42 (84%) | 2 (22%) | 40 (98%) | ||
| Telbivudine | 50 | <0.001 | |||
| No sequence | 8 (16%) | 7 (78%) | 1 (2.4%) | ||
| Resistant | 4 (8.0%) | 0 (0%) | 4 (9.8%) | ||
| Susceptible | 38 (76%) | 2 (22%) | 36 (88%) | ||
|
1
Median (IQR); n (%)
2
Wilcoxon rank sum test; Fisher's exact test
|
|||||